Ingenix announced that health outcomes expert Marc L. Berger, M.D., has joined its Life Sciences division as executive vice president and senior scientist.
Ingenix Life Sciences helps pharmaceutical, biotechnology and medical device organizations identify, analyze and measure the value of their products.
Dr. Berger has more than 30 years of experience in clinical practice and health outcomes research, with a recent focus on the collection and analysis of real-world data. In his new role, he will conduct health economics, outcomes and late-phase research. He reports to William Crown, Ph.D., president of Innovus, which is part of Ingenix Life Sciences.
“Dr. Berger’s expertise in the global field of outcomes research will be an important contribution to Ingenix Life Sciences as we help clients demonstrate the value of their products earlier in the commercialization process,” said Lee Valenta, president, Ingenix Life Sciences. “His wealth of experience and knowledge from working closely with businesses in each of the core market groups we serve – provider, government, life sciences and payer – further differentiate Ingenix Life Sciences’ ability to deliver evocative analysis and insights. We’re thrilled to have Dr. Berger on board.”
“I am impressed with Ingenix Life Sciences’ resources, and inspired by the talent and commitment of its team to help life sciences companies bring meaningful products to patients,” said Dr. Berger. “I look forward to helping Ingenix Life Sciences make a difference for our clients and health communities overall.”
Dr. Berger most recently served as vice president of Global Health Outcomes at Eli Lilly and Co. Previously, he spent 20 years with Merck & Co. in outcomes research and leadership roles.
He is a former board member of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), and co-edited “Health Care, Cost, Quality, and Outcomes: the ISPOR Book of Terms.” In addition, he has served on the Medicare Evidence Development & Coverage Advisory Committee (MedCAC) for the Centers for Medicare & Medicaid Services (CMS) and the steering committee for the Agency for Healthcare Research and Quality (AHRQ) Centers for Research and Education on Therapeutics (CERTs).
Dr. Berger has held adjunct appointments as a senior fellow at the Leonard Davis Institute at the Wharton School at the University of Pennsylvania, and as a professor in the Department of Health Policy and Administration at the University of North Carolina at Chapel Hill School of Public Health. His work has been widely published in peer-reviewed journals on health services, outcomes, economics and policy.
Ingenix, which recently announced it will become OptumInsight, transforms organizations and improves health care through information and technology. Organizations rely on its innovative products, services and consulting to improve the delivery and operations of their business. Through its 13,000 employees around the world, Ingenix serves physicians, hospitals, government agencies, health plans and life sciences companies. For more information about Ingenix, visit www.ingenix.com.